COMMONALITIES BETWEEN FIBROTIC AND INFLAMMATORY MECHANISMS IN PROLIFERATIVE VITREORETINOPATHY AND PROLIFERATIVE DIABETIC RETINOPATHY
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR) share fibrosis and inflammation mechanisms. Understanding these shared pathways is key to developing targeted therapies for vision loss.
Area Of Science
- Ophthalmology
- Retinal Diseases
- Fibrosis Research
Background
- Proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR) are major causes of vision loss.
- Both conditions involve pathological fibrosis and epiretinal membrane formation, driven by inflammation and growth factors.
- While PDR is linked to diabetes and PVR to retinal detachment/trauma, they share common fibrotic pathways.
Purpose Of The Study
- To review the shared mechanisms of fibrosis and inflammation in PDR and PVR.
- To discuss current treatment modalities and their limitations.
- To highlight emerging therapeutic strategies focusing on personalized medicine.
Main Methods
- Literature review of studies on PDR and PVR pathogenesis.
- Analysis of the roles of key cytokines (e.g., TGF-β, VEGF) and cellular processes (e.g., EMT, EndoMT).
- Examination of current and novel therapeutic approaches.
Main Results
- Transforming growth factor-beta (TGF-β) and other growth factors (VEGF, PDGF, CTGF) drive fibrosis via EMT and EndoMT.
- Inflammatory cytokines (TNF-α, interleukins) exacerbate ECM deposition.
- Exosomes, non-coding RNAs, and metabolic alterations also influence the fibrotic microenvironment.
Conclusions
- Current treatments for PDR and PVR have limitations in efficacy and applicability.
- Personalized medicine targeting gene and cell levels shows promise for improved outcomes.
- A deeper understanding of shared fibrotic and inflammatory drivers is crucial for novel therapies to prevent vision loss.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
